Mishima, Japan

Keishi Katayama

USPTO Granted Patents = 2 


Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Keishi Katayama: Innovator in Pharmaceutical Chemistry

Introduction

Keishi Katayama is a prominent inventor based in Mishima, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic potential. With a total of 2 patents to his name, Katayama continues to push the boundaries of innovation in his field.

Latest Patents

Katayama's latest patents include groundbreaking work on imidazole derivatives. One of his notable inventions is a CB2 receptor modulator that comprises an imidazole derivative represented by a specific general formula. This compound is designed to include various substituents, such as optionally substituted lower alkyl, cycloalkyl, and aryl groups, along with pharmaceutically acceptable salts. Additionally, he has developed a fused heterocycle derivative, which is also represented by a general formula, showcasing his expertise in creating complex chemical structures.

Career Highlights

Throughout his career, Keishi Katayama has been associated with Kyowa Hakko Kirin Co., Limited, a leading company in the pharmaceutical industry. His work has been instrumental in advancing the company's research and development efforts, particularly in the area of drug discovery and development.

Collaborations

Katayama has collaborated with several talented individuals in his field, including Naoto Osakada and Takashi Sawada. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

In summary, Keishi Katayama is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug development. His contributions, particularly in the area of imidazole derivatives, highlight his commitment to innovation and excellence in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…